Atezolizumab

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Muscle-invasive Bladder Cancer

Conditions

Muscle-invasive Bladder Cancer

Trial Timeline

May 3, 2021 → Sep 13, 2026

NCT ID

NCT04660344

About Atezolizumab

Atezolizumab is a phase 3 stage product being developed by Roche for Muscle-invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04660344. Target conditions include Muscle-invasive Bladder Cancer.

What happened to similar drugs?

0 of 2 similar drugs in Muscle-invasive Bladder Cancer were approved

Approved (0) Terminated (0) Active (2)

🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3

🔄Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07284121	Pre-clinical	Recruiting	Jul 17, 2025	Dec 31, 2028	Lung Cancer, Hepatocellular Carcinoma
NCT05770102	Phase 2/3	Recruiting	Oct 25, 2023	Oct 1, 2029	Malignancy
NCT05300282	Phase 1/2	Recruiting	Feb 27, 2023	Apr 27, 2030	Relapsed or Refractory Hodgkin's Lymphoma
NCT05047250	Phase 3	Active	Jun 14, 2022	Aug 30, 2027	Non-Small Cell Lung Cancer
NCT05038657	Phase 2	UNKNOWN	May 30, 2022	Jan 1, 2025	Squamous Cell Carcinoma
NCT05171777	Phase 2	Completed	Apr 4, 2022	Oct 25, 2024	Non-small Cell Lung Cancer
NCT05470595	Phase 2	Active	Jan 18, 2022	Jan 31, 2029	Large Cell Neuroendocrine Carcinoma of the Lung
NCT04624399	Phase 2	Recruiting	Jun 17, 2021	May 30, 2026	Urogenital Cancer
NCT04660344	Phase 3	Active	May 3, 2021	Sep 13, 2026	Muscle-invasive Bladder Cancer
NCT04321330	Phase 2	Completed	Aug 7, 2020	Jun 3, 2024	Carcinoma, Thymic
NCT04462276	Phase 2	Completed	Jul 28, 2020	Sep 2, 2024	Small Cell Lung Cancer Extensive Stage
NCT04273061	Phase 2	Recruiting	Jun 17, 2020	Oct 1, 2027	Breast Cancer
NCT03548428	Phase 2	Recruiting	Jun 4, 2020	Feb 4, 2031	Sarcoma
NCT04221529	Phase 2	Completed	Jan 6, 2020	Apr 11, 2025	SCLC, Extensive Stage
NCT03922997	Phase 3	Completed	Jul 3, 2019	Aug 11, 2022	Non-small Cell Lung Cancer
NCT03976518	Phase 2	Completed	May 7, 2019	Feb 12, 2024	Non-Small Cell Lung Cancer
NCT03782207	Pre-clinical	Active	Feb 7, 2019	Jul 31, 2026	Urothelial Carcinoma
NCT03697850	Phase 2	Active	Dec 14, 2018	Feb 15, 2029	Bladder Cancer
NCT03357224	Phase 2	Terminated	Sep 24, 2018	Aug 18, 2022	Lymphoma, T-Cell, Cutaneous
NCT03559647	Pre-clinical	Completed	May 30, 2018	Aug 20, 2023	Non-Small Cell Lung Cancer (NSCLC)

Competing Products

12 competing products in Muscle-invasive Bladder Cancer

See all competitors

Product	Company	Stage	Hype Score
Enfortumab Vedotin + Pembrolizumab	Astellas Pharma	Phase 2	42
Pembrolizumab + Enfortumab Vedotin	Astellas Pharma	Phase 3	44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)	AstraZeneca	Phase 3	44
Durvalumab (Imfinzi) + Tremelimumab	AstraZeneca	Phase 2	27
Pembrolizumab + Gemcitabine	Merck	Phase 2	39
Chemotherapy + Immunotherapy Induction + Immunotherapy Maintenance	Merck	Phase 2	42
Autogene Cevumeran + Nivolumab + Saline	Roche	Phase 2	42
Nivolumab + Nab-paclitaxel + Nivolumab	Bristol Myers Squibb	Phase 2	31
Cretostimogene Grenadenorepvec	CG Oncology	Phase 2	39
CG0070 + Nivolumab	CG Oncology	Phase 1	26
AU-011	Aura Biosciences	Phase 1	26
REOLYSIN® + Gemcitabine + Cisplatin	Oncolytics Biotech	Phase 1	11